Ken Nelson currently serves as partner in the Medtech Advantage Fund, which has an exclusive partnership with Medtech Innovator (www.medtechinnovator.org ), the largest MedTech and Digital Health startup accelerator globally. In addition, he serves as Chairman of the Board for CardiaCare (Rehovot, Israel), and is an active board member for HeartBeam (NASDAQ: BEAT), Acarix (Stockholm, Sweden NASDAQ: ACARIX), Epitel (Salt Lake City, UT), Happitech (Amsterdam, Netherlands), and a handful of other disruptive cardiac Digital Health and MedTech startups. He is also on the advisory boards and/or planning committees, for SmartCardia (Lausanne, Switzerland), HeartX (MedAxiom/ ACC), HRX (Digital Health Summit of Heart Rhythm Society), the Innovation Advisory Board of Heart Rhythm Society (HRS) and on both the Health Tech Innovation Business Advisory Board and Heart & Brain Accelerator of the American Heart Association. He led commercialization for iRhythm, BioTelemetry, and Bardy.